Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Janssen upbeat about latest guselkumab data for patients with psoriatic arthritis

By Brian Buntz | November 18, 2021

Janssen Janssen (NYSE:JNJ) recently presented new data on Tremfya (guselkumab) related to active psoriatic arthritis (PsA) at the American College of Rheumatology (ACR) Convergence while also publishing data in Arthritis & Rheumatology. Notably, guselkumab provided durable joint symptom and disease activity improvement with a consistent safety profile through week 100 in adults with active psoriatic arthritis (PsA).

Guselkumab first won FDA approval in 2017 for treating moderate-to-severe plaque psoriasis. The drug became the first interleukin (IL)-23 inhibitor to win an FDA indication for active PsA in 2020.

“We at Janssen are committed to this IL-23 pathway and understanding how it is driving disease,” said Dr. Alyssa Johnsen, vice president, rheumatology and maternal-fetal immunology disease area leader at Janssen. The pathway is “very important for psoriatic arthritis and psoriasis, and we continue to investigate where it might be able to help patients and address unmet need,” she added.

Janssen's Tremfya

Tremfya (guselkumab) won FDA approval for adult patients with active psoriatic arthritis in 2020.

Guselkumab remains the only IL-23 inhibitor to win U.S. approval to treat both adults with active PsA and adults with moderate to severe plaque psoriasis.

Some of the most notable new data relate to the DISCOVER-2 Phase 3 trial focusing on patients with active PsA.

That study showed that a majority of biologic-naïve adults with PsA receiving guselkumab had improved joint signs and symptoms based on the American College of Rheumatology (ACR 20/50/70) scale. A majority also had complete skin clearance as measured by the Investigator’s Global Assessment (IGA 0).

While guselkumab had a consistent safety profile across the DISCOVER-2 Phase 3 trial, Janssen has five-year data for its use in psoriasis. “While the disease is different, we can still look across all of those studies and look at the safety profile and see the consistent safety profile when we look at our psoriasis data and our data for psoriatic arthritis at six months, at one year and now at two years,” Johnsen said.

Janssen also presented data related to its DISCOVER-1 and -2 trials at ACR Convergence, showing that guselkumab inhibited radiographic progression compared with placebo while supporting durable improvements in joint signs and symptoms.

To identify radiographic progression, a radiologist looks at X-rays to joint damage. “There’s a rather elaborate scale they use to assess whether the joints are more narrow or whether there is erosion,” Johnsen said. “And that just gets measured over time.”

The need to gather data at relatively long intervals in psoriatic arthritis is one of the reasons for long-running clinical trials related to the disease. “It’s a relatively slow process,” Johnsen said. “There was minimal radiographic progression in the DISCOVER-2 trial for the patients on guselkumab, which is great news because we had seen data at six months to a year, and now we’re looking at two years.”


Filed Under: Rheumatology
Tagged With: guselkumab, IL-23 inhibitor, Janssen, PsA, psoriatic arthritis., Tremfya
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Rosnilimab phase 2b trial shows promise in treating RA
rosnilimab
PD-1 agonists show promise in treating rheumatoid arthritis by restoring immune balance 
Zai Lab
Zai Lab’s unified approach to tackling cancer, autoimmune, and neurological diseases
Johnson & Johnson
How a J&J exec found her calling in autoantibody drug development
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE